Natalizumab Elan Pharma Europeiska unionen - svenska - EMA (European Medicines Agency)

natalizumab elan pharma

elan pharma international ltd. - natalizumab - crohnsjukdom - immunstimulatorer, - behandling av måttlig till svår aktiv crohns sjukdom för minskning av tecken och symtom, och induktion och underhåll av varaktig respons och remission, i patienter som inte har svarat trots fullständig och adekvat naturligtvis av behandling med en kortikosteroid och en immunosuppressant, eller som är intoleranta eller har medicinska kontraindikationer för sådana behandlingar.

Tyruko Europeiska unionen - svenska - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Tysabri Europeiska unionen - svenska - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - multipel skleros - selektiva immunsuppressiva medel - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Dimethyl fumarate Neuraxpharm Europeiska unionen - svenska - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Fingolimod Amarox 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod amarox 0,5 mg kapsel, hård

amarox pharma gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne

Fingolimod Aristo 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod aristo 0,5 mg kapsel, hård

aristo pharma gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - natriumlaurilsulfat hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne

Fingolimod Medical Valley 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod medical valley 0,5 mg kapsel, hård

medical valley invest ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Fingolimod Unimedic Pharma 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod unimedic pharma 0,5 mg kapsel, hård

unimedic pharma ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Fingolimod Avansor 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod avansor 0,5 mg kapsel, hård

avansor pharma oy - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Fingolimod STADA 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod stada 0,5 mg kapsel, hård

stada arzneimittel ag - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans